Navigation Links
Cambrex Reports Second Quarter of 2011 Results
Date:8/2/2011

p>$.25$.22Diluted Earnings/(Loss) per Share of Common Stock:   Income from Continuing Operations

$.26$.18   (Loss)/Income from Discontinued Operations, Net of Tax

$

  (0.01)$.04   Net Income

$.25$.22Weighted Average Shares OutstandingBasic29,43329,324Diluted29,49029,402CAMBREX CORPORATIONConsolidated Balance SheetsAs of June 30, 2011 and December 31, 2010(in thousands)June 30,December 31,Assets20112010Cash and Cash Equivalents

$

40,911 $

29,614Trade Receivables, net38,27339,025Inventories, net67,96161,408Prepaid Expenses and Other Current Assets7,8915,082  Total Current Assets155,036135,129Property, Plant and Equipment, net152,057150,483Goodwill40,17737,694Intangible Assets, net4,8984,687Investment in Partially-Owned Affiliate18,87819,709Other Non-Current Assets2,9944,049  Total Assets

$

374,040 $

351,751Liabilities and Stockholders' EquityAccounts Payable

$

19,619 $

19,480Accrued Expenses and Other Current Liabilities36,92633,503Current Portion of Long-term Debt116,400-  Total Current Liabilities172,94552,983Long-term Debt-115,900Deferred Income Taxes18,79017,893Accrued Pension and Postretirement Benefits40,20643,921Other Non-Current Liabilities13,33213,419  Total Liabilities

$

245,273 $

244,116  Stockholders’ Equity

$

128,767 $

107,635  Total Liabilities and Stockholders’ Equity

$

374,040 $

351,751CAMBREX CORPORATIONReconciliation of EBITDAFor the Quarters and Six Months Ended June 30, 2011 and 2010(in thousands)Second Quarter 2011Second Quarter 2010Operating Profit

$

7,294$

6,908Depreciation and Amortization5,8785,226EBITDA

$

13,172$

12,134Six Months 2011Six Months 2010Operating Profit

$

12,601$

10,620Depreciation and Amortization11,60310,610EBITDA

$

24,204$

21,
'/>"/>

SOURCE Cambrex Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Cambrex Reports Third Quarter 2010 Results
2. Cambrex Reports Fourth Quarter and Full Year 2009 Results
3. Cambrex Continuous-Flow Microwave-Assisted Organic Synthesis Technology Nominated for 2009 Innovations Award
4. Cambrex Reports First Quarter 2009 Results
5. Cambrex Receives Notice Regarding NYSE Listing
6. Cambrex Reports Third Quarter 2008 Results
7. Jennerex Reports Positive Mechanistic Proof-of-Concept Clinical Trial Results Using JX-594 to Treat Metastatic Melanoma
8. Gen-Probe Reports Financial Results for the Second Quarter of 2011
9. Neurocrine Biosciences Reports Second Quarter 2011 Results
10. United Therapeutics Corporation Reports Second Quarter 2011 Financial Results
11. Sangamo BioSciences Reports Second Quarter 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... 2014 Nuvilex, Inc. (OTCQB: NVLX) – According ... worldwide are living with diabetes, with  that number expected ... global market for diabetes treatments is approximately $500 billion.  ... died from pancreatic cancer.  Pancreatic cancer is the fourth ... the United States , and according ...
(Date:10/22/2014)... HONG KONG , Oct. 22, 2014 /PRNewswire/ ... announced today that rare disease expert John C. ... research. Dr. McKew brings more than two decades of ... the National Institutes of Health, Wyeth Research and Genetics ... will lead aTyr,s efforts to expand and translate its ...
(Date:10/20/2014)... YORK , Oct. 20, 2014 ... their experimental ZMapp™ antibody therapeutic to fight the ... how difficult and time-consuming the production of pharmaceuticals ... market research publisher said that while some may ... of this compound, those with industry knowledge are ...
(Date:10/20/2014)... 20, 2014 Asterias Biotherapeutics, Inc. (NYSE ... signed a Notice of Grant Award (NGA) with ... October 1, 2014.  The NGA provides for the ... release of additional grant funds pursuant to the ... clinical development of Asterias, product, AST-OPC1. The grant ...
Breaking Biology Technology:Nuvilex Brief Analyst Report: Thinking Outside the Box by BrokerBank Securities, Inc. 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4
... , FORT WORTH, Texas , ... Board: WNDM), announced today that it is nearing the completion of its ... first distributor in that country.  Numerous physicians in the nation have ... with its speed and efficacy in the management of diabetic ulcers ...
... , SAN FRANCISCO , Jan. 13 ... fully configurable system that allows users to design and deploy ... and cost of other providers. Leveraging a background of more ... the Clinical Trial industry, endpoint designed PULSE to balance speed ...
... , ROCHESTER, N.Y. , Jan. ... for biomedical research in the U.S. has decelerated and may have even ... today published in the Journal of the American Medical Association . ... began in the 1990,s has ended," said Ray Dorsey , ...
Cached Biology Technology:Wound Management Technologies, Inc. Rapidly Expands Its International Presence 2Wound Management Technologies, Inc. Rapidly Expands Its International Presence 3Wound Management Technologies, Inc. Rapidly Expands Its International Presence 4endpoint Introduces First Fully Configurable IRT System 2Study: Era of Rapid Growth in Biomedical Research Over 2Study: Era of Rapid Growth in Biomedical Research Over 3Study: Era of Rapid Growth in Biomedical Research Over 4Study: Era of Rapid Growth in Biomedical Research Over 5Study: Era of Rapid Growth in Biomedical Research Over 6
(Date:10/15/2014)... our ability to assess the pandemic risk from strains ... we must not allow ourselves to become complacent that ... international consortium of scientists. , Influenza pandemics arise when ... yet to develop widespread immunity – spreads in the ... the past 100 years, the worst of which – ...
(Date:10/15/2014)... Oct. 15, 2014 NXT-ID, Inc. (NASDAQ: NXTD ... focused on the growing mobile commerce market releases photos and video ... Square on Monday October 13 th . ... Tunnel and angel investor Mr. Chad A. Verdi ... of NXT-ID thanked his investors and employees "for their work and ...
(Date:10/14/2014)... been millions of years since T. rex ... Ohio University scientists is breathing life back into dinosaurs ... snouts. The research has important implications for how dinosaurs ... enhance the sense of smell and cool their brains. ... University doctoral student Jason Bourke, lead author of the ...
Breaking Biology News(10 mins):Scientists 'must not become complacent' when assessing pandemic threat from flu viruses 2Photo Release: NXT-ID Inc. Rings Opening Bell of the NASDAQ Stock Market October 13th 2Photo Release: NXT-ID Inc. Rings Opening Bell of the NASDAQ Stock Market October 13th 3Dinosaur breathing study shows that noses enhanced smelling and cooled brain 2Dinosaur breathing study shows that noses enhanced smelling and cooled brain 3
... 13, 2012) The blood-brain barrier is essential for maintaining ... and isolating the brain,s specific hormonal and neurotransmitter activity from ... addition to nerve cells, the brain contains glia cells that ... blood-brain boundary is made by glia joined into an envelope ...
... DC - On January 18, 2012, Dr. Peter ... National Homeland Security Research Center in the Office ... Protection Agency, will lead a session titled "National ... national resilience to bioterrorism threats involves maximizing advanced ...
... previously un-named species of horse fly whose appearance is dominated ... honour of American pop diva, Beyonc a member of ... single, Bootylicious. , According to the Australian National Insect Collection ... ( Plinthina ) beyonceae , CSIRO,s Bryan Lessard, ...
Cached Biology News:Brain glia cells increase their DNA content to preserve vital blood-brain barrier 2Fly named in honor of Beyonce 2
Mouse monoclonal [N7519] to NR0B2 ( Abpromise for all tested applications). Antigen: E.coli expressed recombinant full length protein (Human) NR0B2 Entrez Gene ID: 8431 Swiss Protein ID: ...
Rabbit polyclonal to BCA1 ( Abpromise for all tested applications). Antigen: Generated using E.coli expressed mouse BCA1. Entrez GeneID: 10563 SWISS Protein ID: O43927...
PKC Sampler Kit 10 mu g each...
Purified anti-SOCS3...
Biology Products: